Sorainen advised Esco Micro, part of the Esco Group, on acquisition of AT Medical – a Lithuania-based manufacturer and developer of innovative in vitro fertilization medical devices. Its products are currently distributed by Esco under the Esco Medical brand. The transaction is expected to close in June 2018.
Under the terms of the agreement, Esco Micro will make an undisclosed payment for the remaining shares in AT Medical. The acquisition price represents a ~16X ROI multiple on the first investment Esco made in AT Medical.
The Esco Group is a renowned Singapore-based life science company with a diversified portfolio and sales in over 100 countries. AT Medical is to be renamed Esco Medical Technologies and will continue operations as a separate legal entity within the Esco Group life science ecosystem.
“We are extremely excited to welcome AT Medical to the Esco family,” commented XQ Lin, Group President & CEO of the Esco Group. “This strengthens our commitment to innovation within the fast-growing fertility technologies market, leveraging the Esco Group’s global network to accelerate product development and drive distribution. Furthermore, it is a successful example of Singaporean-European collaboration in the life sciences field.”
Sorainen advised the client on all legal matters related to this transaction.
The Sorainen team led by partner Sergej Butov included legal assistants Ieva Krivickaitė and Augustė Bučytė.
